Table 1.

Data sets used for evaluation of pediatric PK predictions

Study	Dose, mg/kg i.v.	N	Age, years	Weight, kg
Inflammatory bowel disease
Candon et al.15	Induction with 5	20	10.5 [0.5–15]	NA
Hyams et al.16, 17	Induction with 5 then 5 q8w and q12w with dose escalation to 10	112	13.3 ± 2.5	43.8 ± 14.6
Hamalainen et al.18	Induction with 5 then 5 q8w	37	14 [5.6–18]	43.5 [19.6–67.1]
Baldassano et al.19	1, 5, and 10 single dose	21	15.1 [8–17]	49.1
Singh et al.20	Induction with 5 then 5 q8w	58	11.4 [6.6–18.4]	NA
Adedokun et al.21	Induction with 5 then 5 q8w and q12w with dose escalation	60	14.5 [6–17]	50.8 (36.3–59.4)
Juvenile idiopathic arthritis
Ruperto et al.22	Induction with 3 or 6 then 3 or 6 q8w	122	11.2 [4–18]	NA

Data presented as mean or median and [range], (interquartile range), or ± SD. “Induction” refers to intensive dosing at weeks 0, 2, and 6 before regular maintenance dosing.

NA, not applicable; PK, pharmacokinetic.